RESUMEN
BACKGROUND: Older adults are increasing in number and frequently seeking hospital care for acute illness. We aimed to measure the utilization and safety of ERCP in patients aged 85 and older in our hospital. METHODS: This is a single-site, retrospective, observational and descriptive study. We obtained data about admissions and ERCP utilization from our hospital database. We reviewed medical and procedural records of patients aged 85 or older who underwent ERCP for choledocholithiasis between 2013 and 2019. We evaluated technical and medical adverse events after ERCP. RESULTS: 494 ERCP for choledocholithiasis were performed during this period and 154 (31%) were aged 85 or older. We identified 567 (4.8%) admissions for biliary tract diseases in the older population, and 27% of cases had required ERCP. In older patients, the rate of technical adverse events was around 10%. There was no statistical difference between the older and younger groups regarding technical complications (8.8 vs 9.7%; p=0.7). Besides, in 36% of cases, a medical event, decompensated comorbidity or geriatric syndromes appeared after ERCP. The overall mortality for any cause at six months was nearly 20%, and the survival rate was significantly lower in patients who develop adverse events (technical or medical). CONCLUSIONS: Our hospital experiences frequent utilization of ERCP by patients aged 85 and older. Although technical adverse event rates are similar to those of younger adults, medical events appear frequently. We plan to strengthen our care plans for older adults and hope to reduce the medical complications experienced post ERCP.
RESUMEN
[This corrects the article DOI: 10.1371/journal.pone.0208112.].
RESUMEN
BACKGROUND AND AIMS: Data from clinical trials suggest that biological drugs may improve the outcomes in Crohn's disease (CD) by reducing the need for surgery or hospitalization. The aim of this study is to evaluate the time-trends of the use of biological drugs and other treatments for CD, and its relationship with outcomes in Catalonia. MATERIALS AND METHODS: All patients with CD included in the Catalan Health Surveillance System (containing data on a population of more than 7.5 million) from 2011 to 2017 were identified. The exposures to different treatments for inflammatory bowel disease were retrieved from electronic invoicing records. RESULTS: Between 2011 and 2017, the use of salicylates, corticosteroids and immunosuppressive treatment fell from 28.8% to 17.1%, 15.8% to 13.7%, and 32.9% to 29.6%, respectively (p < 0.001). Biological treatment use rose from 15.0% to 18.7% (p < 0.001). Ostomy rates per 1000 patients/year fell from 13.2 in 2011 to 9.8 in 2017 (p = 0.003), and surgical resection rates from 24.1 to 18.0 (p < 0.001). The rate of CD-related hospitalizations per 1000 patients/year also fell, from 92.7 to 72.2 (p < 0.001). CONCLUSIONS: Biological drug use rose from 15.0% to 18.7% between 2011 and 2017. During this period, we observed an improvement in the outcomes of CD patients.
RESUMEN
BACKGROUND AND AIM: Treatment of hepatitis C with direct-acting antiviral agents (DAA) has few side effects. Although pivotal studies suggested that DAA were safe in patients with psychiatric diseases who could not be treated with previous antiviral therapies, their effects on anxiety and depression have not yet been analysed in clinical practice. The aim of our study was to analyse anxiety and depression in the setting of DAA treatment in a clinical practice series. METHODS: All patients starting DAA treatment between November 1, 2014 and October 31, 2015 were eligible. Patients completed the Hospital Anxiety and Depression scale at different times during treatment. The results were plotted on line graphs and evaluated using a linear regression model with repeated measures. RESULTS: One hundred and forty-five patients were included (11% with major psychiatric disorders; 32% on psychiatric treatment). Sustained virologic response (SVR) was achieved in 97.3% of cases. Anxiety and depression measures did not differ between time points. No differences between patients on psychiatric treatment or with advanced fibrosis or cirrhosis were found at any time point analysed. CONCLUSION: DAA treatment had no impact on anxiety or depression during or after chronic hepatitis C infection treatment, even in high-risk patients with major psychiatric disorders.
Asunto(s)
Antivirales/efectos adversos , Ansiedad/epidemiología , Depresión/epidemiología , Hepatitis C Crónica/tratamiento farmacológico , Trastornos Mentales/epidemiología , Anciano , Antivirales/administración & dosificación , Ansiedad/inducido químicamente , Ansiedad/diagnóstico , Comorbilidad , Depresión/inducido químicamente , Depresión/diagnóstico , Femenino , Hepacivirus/efectos de los fármacos , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica/epidemiología , Hepatitis C Crónica/psicología , Hepatitis C Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Cuestionario de Salud del Paciente/estadística & datos numéricos , Estudios Prospectivos , Respuesta Virológica SostenidaRESUMEN
UNLABELLED: Background. Despite the introduction of direct antiviral agents, pegylated interferon remains the mainstay of treatment for chronic hepatitis C. However, pegylated interferon is associated with a high rate of severe adverse events and decreased quality of life. Specific interventions can improve adherence and effectiveness. We aimed to determine whether implementing a multidisciplinary approach improved outcomes in the treatment of chronic hepatitis C. MATERIAL AND METHODS: We analyzed consecutive patients treated with pegylated interferon plus ribavirin between August 2001 and December 2011. We compared patients treated before and after the implementation of a multidisciplinary approach in 2007. We compared the baseline demographic and clinical characteristics and laboratory findings between groups, and used bivariate logistic regression models to detect factors involved in attaining a sustained virological response, calculating the odds ratios with their respective 95% confidence intervals. To evaluate the effect of the multidisciplinary team, we fitted a multivariate logistic regression model to compare the sustained virological response after adjusting for unbalanced variables and predictive factors. RESULTS: We included 514 patients [228 (44.4%) in the pre-intervention cohort]. Age, viral genotype, previous treatment, aspartate transaminase, ferritin, and triglyceride were prognostic factors of sustained virological response. After adjusting for prognostic factors, sustained virological response was higher in the multidisciplinary cohort (58 vs. 48%, p = 0.038). Despite higher psychiatric comorbidity and age in the multidisciplinary cohort, we observed a trend toward a lower rate of treatment abandonment in this group (2.2 vs. 4.9%, p = 0.107). CONCLUSION: Multidisciplinary management of chronic hepatitis C improves outcomes.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Grupo de Atención al Paciente , Polietilenglicoles/uso terapéutico , Adulto , Factores de Edad , Aspartato Aminotransferasas/sangre , Dermatólogos , Quimioterapia Combinada , Femenino , Ferritinas/sangre , Gastroenterólogos , Genotipo , Hepacivirus/genética , Hepatitis C Crónica/sangre , Humanos , Interferón alfa-2 , Modelos Logísticos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , Enfermeras y Enfermeros , Educación del Paciente como Asunto , Farmacéuticos , Pronóstico , Psiquiatría , Calidad de Vida , ARN Viral/sangre , Proteínas Recombinantes/uso terapéutico , Respuesta Virológica Sostenida , Resultado del Tratamiento , Triglicéridos/sangreRESUMEN
INTRODUCTION: Because of the current overload of emergency services, new units, such as day units, have had to be created. Liver cirrhosis (LC) is a chronic disease with frequent decompensations requiring medical attention. The aim of this study was to compare differences between emergency consultations in a hepatology day hospital (HDH) and in an emergency service (ES) among patients with LC. METHODS AND MATERIAL: We performed an observational prospective study. All patients with LC attending the HDH or ES from September 2007 to August 2008 were asked to complete a questionnaire. Demographic, clinical, and radiological variables were collected. RESULTS: There were 743 consultations, of which 62% involved the HDH. The mean age was 65±12 years, and the male/female ratio was 2:3. The most frequent diagnosis in the ES was hepatic encephalopathy (26.2% ES versus 6% HDH, p<0.001) followed by upper gastrointestinal hemorrhage (17.7% ES versus 0.6% HDH, p<0.001), while the most frequent diagnosis in the HDH was ascites (66.2% HDH versus 22.7% ES, p<0.001). The tests performed were as follows: blood analysis: 95% ES versus 60% HDH (p<0.01); radiology: 71% ES versus 11% HDH (p<0.01) and paracentesis: 51% ES versus 74% HDH (p<0.01). The mean length of stay in the ES was 21.3±121.5 hours compared with 3.3±2.4 hours in the HDH (p<0.001). A total of 53% of patients attended in the ES were hospitalized compared with 12% of those attended in the HDH (p<0.05). CONCLUSION: Patients with LC preferentially attend the HDH, where fewer tests are performed and the length of stay is shorter. The care provided in the HDH is appropriate and efficient.
Asunto(s)
Centros de Día/estadística & datos numéricos , Servicios Médicos de Urgencia/estadística & datos numéricos , Cirrosis Hepática , Anciano , Femenino , Gastroenterología , Hospitales Especializados , Humanos , Cirrosis Hepática/terapia , Masculino , Estudios ProspectivosRESUMEN
Introducción El colapso actual de los servicios de urgencias ha originado el desarrollo de otros ámbitos de atención como los hospitales de día. La cirrosis hepática (CH) es una enfermedad crónica que presenta descompensaciones que requieren atención. El objetivo es comparar las diferencias entre las visitas urgentes de los pacientes con CH al hospital de día de hepatología (HDH) o al servicio de urgencias (URG).Material y métodos Estudio prospectivo observacional, mediante la complementación de un cuestionario de los pacientes que acudieron al HDH y a URG entre 9/2007 y 8/2008. Se recogieron variables demográficas, clínicas y exploraciones complementarias realizadas. Resultados Hubo 743 consultas, 62% al HDH. La edad media fue de 65±12 años, ratio hombre/mujer 2,3. El diagnóstico más frecuente en URG fue la encefalopatía (26,2% URG versus 6% HDH, p<0,001) seguido de la hemorragia digestiva alta (17,7% URG versus 0,6% HDH, p<0,001). La ascitis fue el más frecuente en HDH (66,2% HDH versus 22,7% URG, p<0,001). Las exploraciones realizadas fueron, análisis: 95% URG versus 60% HDH (p<0,01); radiología: 71% URG versus 11% HDH (p<0,01), y paracentesis: 51% URG versus 74% HDH (p<0,01). El tiempo de estancia en URG fue de 21,3±121,5 h respecto a 3,3±2,4 h en HDH (p<0,001). Se hospitalizaron el 53% de los visitados en URG y el 12% de los visitados en HDH (p<0,05).Conclusión los pacientes acuden mayoritariamente al HDH, realizándose menos pruebas y presentando un tiempo de estancia menor. La atención continuada de pacientes con CH en el HDH es adecuada y eficiente (AU)
Introduction Because of the current overload of emergency services, new units, such as day units, have had to be created. Liver cirrhosis (LC) is a chronic disease with frequent decompensations requiring medical attention. The aim of this study was to compare differences between emergency consultations in a hepatology day hospital (HDH) and in an emergency service (ES) among patients with LC. Methods and material We performed an observational prospective study. All patients with LC attending the HDH or ES from September 2007 to August 2008 were asked to complete a questionnaire. Demographic, clinical, and radiological variables were collected. Results There were 743 consultations, of which 62% involved the HDH. The mean age was 65±12 years, and the male/female ratio was 2:3. The most frequent diagnosis in the ES was hepatic encephalopathy (26.2% ES versus 6% HDH, p<0.001) followed by upper gastrointestinal hemorrhage (17.7% ES versus 0.6% HDH, p<0.001), while the most frequent diagnosis in the HDH was ascites (66.2% HDH versus 22.7% ES, p<0.001). The tests performed were as follows: blood analysis: 95% ES versus 60% HDH (p<0.01); radiology: 71% ES versus 11% HDH (p<0.01) and paracentesis: 51% ES versus 74% HDH (p<0.01). The mean length of stay in the ES was 21.3±121.5hours compared with 3.3±2.4hours in the HDH (p<0.001). A total of 53% of patients attended in the ES were hospitalized compared with 12% of those attended in the HDH (p<0.05).Conclusion Patients with LC preferentially attend the HDH, where fewer tests are performed and the length of stay is shorter. The care provided in the HDH is appropriate and efficient (AU)
Asunto(s)
Humanos , Cirrosis Hepática/epidemiología , Servicios Médicos de Urgencia/estadística & datos numéricos , Atención Ambulatoria/estadística & datos numéricos , Distribución por Edad y Sexo , Estudios Prospectivos , Centros de Día , Tratamiento de Urgencia/estadística & datos numéricosRESUMEN
BACKGROUND: Few data are available on the prevalence of erosive and severe esophagitis in Western countries. OBJECTIVE: To retrospectively determine the prevalence and the factors predicting erosive esophagitis and severe esophagitis in a large series of endoscopies in Spain. DESIGN: Retrospective observational study. A multivariate analysis was performed to determine variables predicting severe esophagitis. SETTING: Databases of 29 Spanish endoscopy units. PATIENTS: Patients submitted to a diagnostic endoscopy during the year 2005. INTERVENTIONS: Retrospective review of the databases. MAIN OUTCOME MEASUREMENTS: Esophagitis severity (graded according to the Los Angeles classification) and associated endoscopic findings. RESULTS: Esophagitis was observed in 8.7% of the 93,699 endoscopies reviewed. Severe esophagitis (LA grade C or D) accounted for 22.5% of cases of the disease and was found in 1.9% of all endoscopies. Incidences of esophagitis and those of severe esophagitis were 86.2 and 18.7 cases per 100,000 inhabitants per year respectively. Male sex (OR 1.89) and advanced age (OR 4.2 for patients in the fourth age quartile) were the only variables associated with severe esophagitis. Associated peptic ulcer was present in 8.8% of cases. LIMITATIONS: Retrospective study, no data on individual proton pump inhibitors use. CONCLUSIONS: Severe esophagitis is an infrequent finding in Spain. It occurs predominantly in males and in older individuals. Peptic ulcer disease is frequently associated with erosive esophagitis.
Asunto(s)
Esofagitis/epidemiología , Esofagitis/microbiología , Helicobacter pylori/fisiología , Úlcera Péptica/complicaciones , Úlcera Péptica/epidemiología , Índice de Severidad de la Enfermedad , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Endoscopía , Esofagitis/complicaciones , Esofagitis/patología , Femenino , Geografía , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Prevalencia , Derivación y Consulta , Factores de Riesgo , España/epidemiología , Adulto JovenRESUMEN
Las perforaciones del tracto digestivo representan una fuente de morbilidad en la práctica clínica. Clásicamente el manejo de las perforaciones ha sido quirúrgico. En ocasiones, cuando son de pequeño tamaño el tratamiento endoscópico con clips puede resolverla. Sin embargo, la aparición del NOTES (cirugía endoscópica transluminal a través de orificios naturales) ha contribuido de una manera notable a la investigación de nuevas tecnologías que consiguen el cierre endoscópico de las perforaciones del tracto digestivo. Entre ellas el sistema OVESCO, u OTSC (acrónimo del inglés, over the scope clip), constituye por su eficacia, seguridad y rapidez uno de los sistemas más prometedores para el cierre de las perforaciones del tracto digestivo. Otras aplicaciones de este sistema son la hemorragia digestiva grave, las fístulas, los fallos de anastomosis, y su remodelación en la cirugía bariátrica. Este artículo revisa el sistema OVESCO desde su diseño hasta la introducción en la práctica clínica (AU)
Perforations of the gastrointestinal tract are a significant source of morbidity in clinical practice. Surgery has been the standard of care. However, endoscopic treatment with clips can be used when perforations are small. The development of natural orifice transluminal endoscopic surgery (NOTES) has substantially contributed to research in this field, such as the over the scope clip (OVESCO or OTSC). This system is one of the most promising technologies for closure of perforations of the gastrointestinal tract because of its efficacy, safety and rapidity. Other indications include severe gastrointestinal bleeding, fistulae, anastomotic leaks, and bariatric surgery anastomosis remodelling. This article describes the OVESCO system from its initial design to its introduction in clinical practice (AU)
Asunto(s)
Humanos , Perforación Intestinal/cirugía , Cirugía Endoscópica por Orificios Naturales/métodos , Endoscopía Gastrointestinal/métodos , Fístula del Sistema Digestivo/cirugía , Hemorragia Gastrointestinal/cirugíaRESUMEN
Perforations of the gastrointestinal tract are a significant source of morbidity in clinical practice. Surgery has been the standard of care. However, endoscopic treatment with clips can be used when perforations are small. The development of natural orifice transluminal endoscopic surgery (NOTES) has substantially contributed to research in this field, such as the over the scope clip (OVESCO or OTSC). This system is one of the most promising technologies for closure of perforations of the gastrointestinal tract because of its efficacy, safety and rapidity. Other indications include severe gastrointestinal bleeding, fistulae, anastomotic leaks, and bariatric surgery anastomosis remodelling. This article describes the OVESCO system from its initial design to its introduction in clinical practice.
Asunto(s)
Endoscopía Gastrointestinal/instrumentación , Perforación Intestinal/cirugía , Estómago/lesiones , Ensayos Clínicos como Asunto , Fístula del Sistema Digestivo/cirugía , Endoscopía Gastrointestinal/métodos , Diseño de Equipo , Hemorragia Gastrointestinal/cirugía , Hemostasis Quirúrgica/instrumentación , Humanos , Instrumentos Quirúrgicos , Heridas y Lesiones/cirugíaRESUMEN
BACKGROUND AND AIMS: Histological and rapid urease tests to detect H. pylori in biopsy specimens obtained during peptic ulcer bleeding episodes (PUB) often produce false-negative results. We aimed to examine whether immunohistochemistry and real-time PCR can improve the sensitivity of these biopsies. PATIENTS AND METHODS: We selected 52 histology-negative formalin-fixed paraffin-embedded biopsy specimens obtained during PUB episodes. Additional tests showed 10 were true negatives and 42 were false negatives. We also selected 17 histology-positive biopsy specimens obtained during PUB to use as controls. We performed immunohistochemistry staining and real-time PCR for 16S rRNA, ureA, and 23S rRNA for H. pylori genes on all specimens. RESULTS: All controls were positive for H. pylori on all PCR assays and immunohistochemical staining. Regarding the 52 initially negative biopsies, all PCR tests were significantly more sensitive than immunohistochemical staining (p<0.01). Sensitivity and specificity were 55% and 80% for 16S rRNA PCR, 43% and 90% for ureA PCR, 41% and 80% for 23S rRNA PCR, and 7% and 100% for immunohistochemical staining, respectively. Combined analysis of PCR assays for two genes were significantly more sensitive than ureA or 23S rRNA PCR tests alone (p<0.05) and marginally better than 16S rRNA PCR alone. The best combination was 16S rRNA+ureA, with a sensitivity of 64% and a specificity of 80%. CONCLUSIONS: Real-time PCR improves the detection of H. pylori infection in histology-negative formalin-fixed paraffin-embedded biopsy samples obtained during PUB episodes. The low reported prevalence of H. pylori in PUB may be due to the failure of conventional tests to detect infection.
Asunto(s)
Helicobacter pylori/aislamiento & purificación , Hemorragia/microbiología , Úlcera Péptica/microbiología , Reacción en Cadena de la Polimerasa/métodos , Adulto , Anciano , Secuencia de Bases , Biopsia , Cartilla de ADN , Genes Bacterianos , Helicobacter pylori/genética , Hemorragia/complicaciones , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Úlcera Péptica/complicaciones , Úlcera Péptica/patología , ARN Ribosómico 16S/genética , Especificidad de la EspecieRESUMEN
OBJECTIVES: It has been suggested that prevalence of Helicobacter pylori (Hp) in peptic ulcer bleeding (PUB) is lower than that in non-complicated ulcers. As Hp infection is elusive in PUB, we hypothesized that this low prevalence could be related to an insufficiently intensive search for the bacteria. The aim of the study was to evaluate whether the prevalence of Hp in PUB depends on the diagnostic methods used in a given study. METHODS: A systematic review was performed of studies assessing the prevalence of Hp infection in patients with PUB. Data were extracted in duplicate. Univariate and multivariate random-effects meta-regression analyses were performed to determine the factors that explained the differences in Hp prevalence between studies. RESULTS: The review retrieved 71 articles, including 8,496 patients. The mean prevalence of Hp infection in PUB was 72%. The meta-regression analysis showed that the most significant variables associated with a high prevalence of Hp infection were the use of a diagnostic test delayed until at least 4 weeks after the PUB episode-odds ratio: 2.08, 95% confidence interval: 1.10-3.93, P=0.024-and a lower mean age of patients-odds ratio: 0.95 per additional year, 95% confidence interval: 0.92-0.99, P=0.008. CONCLUSIONS: Studies that performed a delayed test and those including younger patients found a higher prevalence of Hp, approaching that recorded in cases of non-bleeding ulcers. These results suggest that the low prevalence of Hp infection described in PUB may be related to the methodology of the studies and to patients' characteristics, and that the true prevalence of Hp in PUB is still to be determined. Our data also support the recent recommendations of the International Consensus on Non-Variceal Upper Gastrointestinal Bleeding regarding the performance of a delayed diagnostic test when Hp tests carried out during the acute PUB episode are negative.
Asunto(s)
Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Úlcera Péptica Hemorrágica/microbiología , Análisis de Varianza , Asia/epidemiología , Australia/epidemiología , Europa (Continente)/epidemiología , Infecciones por Helicobacter/complicaciones , Humanos , América del Norte/epidemiología , Oportunidad Relativa , Prevalencia , Análisis de Regresión , América del Sur/epidemiologíaRESUMEN
BACKGROUND: Studies comparing new monoclonal fecal tests for evaluating cure of Helicobacter pylori infection after treatment are scarce. The objective was to compare the diagnostic accuracy of three monoclonal stool tests: two rapid in-office tools -RAPID Hp StAR and ImmunoCard STAT! HpSA - and an EIA test - Amplified IDEIA Hp StAR. MATERIALS AND METHODS: Diagnostic reliability of the three tests was evaluated in 88 patients at least 8 weeks after H. pylori treatment. Readings of immunochromatographic tests were performed by two different observers. Sensitivity, specificity, positive and negative predictive values and 95% confidence intervals were calculated. RESULTS: All tests presented similar performance for post-eradication testing. Sensitivity for detecting persistent infection was 100% for both Amplified IDEIA and RAPID Hp StAR and 90% for ImmunoCard STAT! HpSA. Respective specificities were 94.9%, 92.3-93.6% and 94.9%. Negative predictive values were very high (100%, 100% and 98.7% respectively). But positive predictive values were lower, ranging from 62.5 to 71.4%. CONCLUSION: All monoclonal fecal tests in this series presented similar performance in the post-treatment setting. A negative test after treatment adequately predicted cure of the infection. However, nearly a third of tests were false positive, showing a poor predictive yield for persistent infection.
Asunto(s)
Anticuerpos Antibacterianos , Anticuerpos Monoclonales , Monitoreo de Drogas/métodos , Heces/microbiología , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Adulto , Anciano , Reacciones Falso Positivas , Femenino , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Inmunoensayo , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: Well-devised studies comparing new but different monoclonal fecal tests for diagnosing Helicobacter pylori infection are scarce. The objective of this study was to compare the diagnostic accuracy of 3 monoclonal stool tests: 2 rapid in-office tools-RAPID Hp StAR and ImmunoCard STAT! HpSA-and an enzyme immunoassay test-Amplified IDEIA Hp StAR-for diagnosing H. pylori infection prior to eradication treatment. METHODS: Diagnostic reliability was evaluated in 199 untreated consecutive patients with dyspeptic symptoms. The gold standard for diagnosing H. pylori infection was defined as the concordance of the rapid urease test, histopathology, and urea breath test. Readings of immunochromatographic tests were performed by 2 different observers. Sensitivity, specificity, positive and negative predictive values, and 95% confidence intervals were calculated. Sensitivity and specificity were compared using the McNemar test. RESULTS: The sensitivity and specificity of Amplified IDEIA Hp StAR were 90% and 89%, respectively. This enzyme immunoassay test was significantly more sensitive than ImmunoCard STAT! HpSA and more specific than RAPID Hp StAR. The sensitivity and specificity of RAPID Hp StAR were 91% and 80%, respectively, according to observer 1, and 92% and 76%, respectively, according to observer 2. It was significantly more sensitive and less specific than ImmunoCard STAT! HpSA. The sensitivity and specificity of ImmunoCard STAT! HpSA were 69% and 90%, respectively, according to observer 1, and 74% and 89%, respectively, according to observer 2. CONCLUSIONS: Amplified IDEIA Hp StAR seems to be the most accurate stool test for diagnosing H. pylori for patients with dyspeptic symptoms. The currently available in-office tests obtain slightly less reliable results.
Asunto(s)
Anticuerpos Antibacterianos , Anticuerpos Monoclonales , Antígenos Bacterianos/análisis , Dispepsia/microbiología , Heces/microbiología , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Adulto , Pruebas Respiratorias , Heces/química , Femenino , Humanos , Inmunoensayo/métodos , Masculino , Persona de Mediana Edad , Juego de Reactivos para Diagnóstico , Sensibilidad y Especificidad , Ureasa/análisisRESUMEN
INTRODUCTION: Numerous clinical trials have demonstrated the efficacy of treatment with pegylated interferon and ribavirin but little is known about the results obtained in clinical practice. OBJECTIVE: To evaluate treatment response and factors influencing the treatment of chronic hepatitis C in clinical practice. MATERIAL AND METHODS: Between August 2001 and December 2005, we treated 219 patients with pegylated interferon (alpha 2a -fixed dose, or alpha 2b, according to weight) and ribavirin. Patients with genotype 1 or 4 received treatment with pegylated interferon alpha 2a (180 microg/week) and ribavirin (1000 mg/day if body weight was <75 kg or 1200 mg/day if body weight was >75 kg) or interferon alpha 2b (1.5 microg/kg/week) and ribavirin (10.6 mg/kg/day) for 48 weeks. Patients with genotype 2 or 3 were treated for 24 weeks with the same regimen of pegylated interferon alpha-2a or alpha-2b, but with 800 mg of ribavirin divided in two daily doses. Sustained viral response was defined as absence of HCV-RNA 6 months after the end of treatment. RESULTS: A total of 219 patients were included (69% men; mean age 44+/-10). As epidemiological antecedents, 22.4% of the treated patients had previously consumed drugs parenterally and 22.4% had received blood transfusions before 1992. Forty-seven percent of the patients with liver biopsy had fibrosis bridges or established liver cirrhosis. The genotype was distributed as follows: 69.8% genotype 1, 4.1% genotype 2, 17.8% genotype 3, and 8.2% genotype 4. Of the 219 patients, 76 (35%) were treated with pegylated interferon alpha 2a and 143 (65%) with interferon alpha 2b. Analysis of response by genotype revealed that sustained viral response was obtained in 46% genotype 1, 88.9% genotype 2, 78.9% genotype 3, and 33.3% genotype 4. Univariate analysis showed that the only variable influencing sustained viral response was genotype. CONCLUSION: Treatment with pegylated interferon and ribavirin in clinical practice shows a similar pattern of sustained viral response to that obtained in clinical research. The main variable correlated with sustained viral response continues to be viral genotype.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Polietilenglicoles/uso terapéutico , Ribavirina/uso terapéutico , Adulto , Femenino , Humanos , Interferón alfa-2 , Masculino , Proteínas Recombinantes , Factores de TiempoRESUMEN
INTRODUCCIÓN: Numerosos ensayos clínicos demuestran unaalta eficacia en el tratamiento con interferón pegilado y ribavirina;sin embargo, se conoce poco sobre los resultadosobtenidos en la práctica clínica.OBJETIVO: Evaluar en la práctica clínica la respuesta y losfactores que influyen en el tratamiento de la hepatitis crónicapor el virus C.MATERIAL Y MÉTODOS: Entre agosto de 2001 y diciembre de2005, se trató a 219 pacientes con interferón pegilado (alfa-2a en dosis fijas o alfa-2b según el peso) y ribavirina. Lospacientes que presentaban un genotipo 1 o 4 recibieron tratamientocon interferón pegilado alfa-2a (180 g/semana) yribavirina (1.000 mg/día si < 75 kg o 1.200 mg/día si > 75 kg)o interferón alfa-2b (1,5 g/kg/semana) y ribavirina (10,6mg/kg/día) durante 48 semanas. Los pacientes con genotipo2 y 3 fueron tratados durante 24 semanas con la misma pautade interferón pegilado alfa-2a o alfa-2b, pero con 800 mgde ribavirina al día repartida en dos dosis. La respuesta viralsostenida (RVS) se ha determinado como la negatividaddel ARN del virus de la hepatitis C a los 6 meses después definalizar el tratamiento.RESULTADOS: Se incluyeron 219 pacientes (un 69% varones,con una edad de 44 ± 10 años). Como antecedentes epidemiológicos,un 22,4% había consumido drogas por vía parenteraly un 22,4% había sido transfundido antes del año 1992.Un 47% de los pacientes con biopsia hepática tenía puentesde fibrosis o cirrosis hepática establecida. Los genotipos sedistribuyeron de la siguiente forma: 69,8% genotipo 1; 4,1%genotipo 2; 17,8% genotipo 3; 8,2% genotipo 4. Del total de219 pacientes, 76 (35%) fueron tratados con interferón pegiladoalfa-2a y 143 (65%) con interferón alfa-2b. Según el genotipo,la RVS se obtuvo en un 46% genotipo 1, un 88,9%genotipo 2, un 78,9% genotipo 3 y un 33,3% genotipo 4. Elanálisis univariado mostró que el genotipo es la única variableque influyó en la RVS. (..)(AU)
INTRODUCTION: Numerous clinical trials have demonstratedthe efficacy of treatment with pegylated interferon and ribavirinbut little is known about the results obtained in clinicalpractice.OBJECTIVE: To evaluate treatment response and factors influencingthe treatment of chronic hepatitis C in clinicalpractice.MATERIAL AND METHODS: Between August 2001 and December2005, we treated 219 patients with pegylated interferon(alpha 2a -fixed dose, or alpha 2b, according to weight) andribavirin. Patients with genotype 1 or 4 received treatmentwith pegylated interferon alpha 2a (180 g/week) and ribavirin(1000 mg/day if body weight was < 75 kg or 1200mg/day if body weight was > 75 kg) or interferon alpha 2b(1.5 g/kg/week) and ribavirin (10.6 mg/kg/day) for 48 weeks.Patients with genotype 2 or 3 were treated for 24 weekswith the same regimen of pegylated interferon alpha-2a oralpha-2b, but with 800 mg of ribavirin divided in two dailydoses. Sustained viral response was defined as absence ofHCV-RNA 6 months after the end of treatment (..) (AU)